Ziopharm Oncology (ZIOP) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St futures muted as US-Iran impasse lifts oil prices
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 4:04 PM EDTEnrollment completed in Controlled IL-12 phase 2 clinical trial with Regenerons Libtayo® First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 Work restrictions at the NCI and MD Anderson easing; MD Anderson initiated phase 1 CD19-specific CAR-T clinical trial using RPM Eden BioCell on track for Taiwan IND filing for autologus CAR-T clinical trial this year
Company to host conference call and webcast today, August 6, at 4:30 p.m. EDT
BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) --... More
